GLP-1 Receptor Agonists Broaden Therapeutic Horizon from Diabetes to MASH
Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for type 2 diabetes, have seen their therapeutic applications expand at an remarkable pace. Beyond managing diabetes and obesity, these agents have demonstrated efficacy in reducing cardiovascular risk, treating obstructive sleep apnea, and addressing chronic kidney disease. A significant milestone occurred in 2025 with the expansion of their treatment target to include Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly NASH).
Novo Nordisk’s Wegovy Receives First FDA Approval for MASH; Eli Lilly’s Foundayo Emerges as Oral Option
A groundbreaking development in the expanding indications of GLP-1RAs was the world’s first FDA approval in August 2025 for Novo Nordisk’s injectable obesity drug, Wegovy (semaglutide), for patients with MASH and moderate to advanced liver fibrosis. This marked the inaugural approval of a GLP-1RA for MASH, heralding a new therapeutic paradigm in liver diseases. Wegovy, in addition to its well-known weight loss benefits, demonstrated potential to improve MASH pathology.
Furthermore, in April 2026, Eli Lilly’s orforglipron (brand name: Foundayo) received approval for obesity treatment. Foundayo is the first oral small-molecule GLP-1 receptor agonist, and it is expected to significantly enhance patient convenience compared to traditional injectable GLP-1RAs. This diversification of GLP-1RA treatment options will broaden access for more patients.
Background and Medical Impact
MASH is a serious liver disease with a growing global prevalence, carrying risks of progression to cirrhosis and liver cancer. Historically, effective treatments have been extremely limited. Wegovy’s approval for MASH provides a powerful solution to this unmet medical need, holding the potential to significantly improve the prognosis for MASH patients.
Moreover, the emergence of oral GLP-1RA like Foundayo expands treatment choices for patients hesitant about injections or seeking more convenient administration routes. The broadening adaptation of GLP-1RAs to various diseases underscores the multifaceted pharmacological actions of this drug class and its extensive therapeutic potential.
Future Outlook
The continued approval of GLP-1 receptor agonists for a diverse range of conditions, including MASH, highlights their versatility and broad clinical utility. Wegovy’s MASH approval is expected to catalyze further research and development in this area, accelerating efforts by other GLP-1RAs to secure MASH indications. The introduction of oral agents like Foundayo will invigorate competition in the GLP-1RA market, further driving improvements in patient convenience and expanding treatment accessibility. Consequently, GLP-1RAs are anticipated to establish themselves as central therapeutics in the management of a wide array of metabolic diseases, including diabetes, obesity, cardiovascular, and liver diseases, in future medical practice.
Source: https://www.drugdiscoverytrends.com/diabetes-to-mash-the-specimens-behind-glp-1s-widening-roster/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments